INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237601, 'Glycerol phenylbutyrate', 'Vorinostat', 'Moderate', 'Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor', 'DDInter', 'The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245215/', '', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, More', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237602, 'Vorinostat', 'Samarium (153Sm) lexidronam', 'Major', 'Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.  In clinical trials, white blood cell and platelet counts decreased to a nadir of approximately 40% to 50% of baseline in 95% of patients within three to five weeks after administration of samarium sm 153 lexidronam, and tended to return to pretreatment levels by eight weeks.  The potential for additive bone marrow toxicity with myelotoxic treatments including chemotherapy or external beam radiation has not been studied.', 'DDInter', 'The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.  Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery.  Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245217/', '', 'Strontium chloride Sr-89', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237603, 'Vorinostat', 'Phenylbutyric acid', 'Moderate', 'Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor', 'DDInter', 'The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245218/', '', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, More', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237604, 'Celecoxib', 'Vortioxetine', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245220/', '', 'Opium, Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, More', 'Phenelzine, Tranylcypromine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237605, 'Vortioxetine', 'Turmeric', 'Moderate', 'Turmeric may potentiate the bleeding risk associated with drugs that interfere with platelet function or coagulation.', 'DDInter', 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.  Clinical and laboratory observation for hematologic complications is recommended.', 'Synergism', 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245237/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237606, 'Pazopanib', 'Apixaban', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp.  However, caution may be advisable.  Closer monitoring of the pharmacologic effects of apixaban may be appropriate whenever a CYP450 3A4 or P-gp inhibitor is added to or withdrawn from therapy.  Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women).', 'Metabolism', 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245344/', '', 'Ticagrelor, Betrixaban, Clopidogrel, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More', 'Dacomitinib, Bosutinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Axitinib, Ripretinib, Lenvatinib, Erlotinib, Osimertinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237607, 'Bacillus calmette-guerin substrain tice live antigen', 'Pazopanib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245349/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237608, 'Bromocriptine', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of bromocriptine.  Orally administered bromocriptine is extensively metabolized in the gastrointestinal tract and liver by CYP450 3A4, with approximately 93% of the absorbed dose undergoing first-pass metabolism and only the remaining 7% reaching systemic circulation.  As such, inhibitors of CYP450 3A4 may markedly reduce the metabolic clearance of bromocriptine.', 'DDInter', 'Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with CYP450 3A4 inhibitors, and the bromocriptine dosage adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245355/', '', 'Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Pergolide, Pramipexole, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237609, 'Drospirenone', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245362/', '', 'Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237610, 'Eltrombopag', 'Pazopanib', 'Major', 'Coadministration with potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations and risk of toxicity of pazopanib.  The proposed mechanism involves inhibition of P-gp- or BCRP-mediated transporters of pazopanib metabolism.', 'DDInter', 'Concomitant use of pazopanib with potent inhibitors of P-gp or BCRP should generally be avoided.  Selection of an alternate concomitant medication with no or minimal potential to inhibit P-gp or BCRP should be considered.  Patients should have liver function tests (ALT, AST, bilirubin), electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling.  Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  In addition, they should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.', 'Metabolism', 'Concomitant use of pazopanib with potent inhibitors of P-gp or BCRP should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245365/', '', 'Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human', 'Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237611, 'Fesoterodine', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.', 'DDInter', 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', 'Metabolism', 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245366/', '', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Oxybutynin, More', 'Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237612, 'Fidaxomicin', 'Pazopanib', 'Moderate', 'Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.', 'DDInter', 'Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245368/', '', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin', 'Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Selumetinib, Ribociclib, Vandetanib, Duvelisib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237613, 'Gefitinib', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.  Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.', 'Metabolism', 'Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245372/', '', 'Regorafenib, Copanlisib, Abemaciclib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Afatinib, Dacomitinib, More', 'Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237614, 'Pazopanib', 'Levobupivacaine', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', 'DDInter', 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil).  Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine).  Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.', 'Metabolism', 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245386/', '', 'Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237615, 'Pazopanib', 'Maraviroc', 'Moderate', 'Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.', 'DDInter', 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.  Dosage adjustment for maraviroc may be necessary if an interaction is suspected.', 'Metabolism', 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245389/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237616, 'Pazopanib', 'Mirabegron', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.  However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination.', 'DDInter', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.  However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination.  In a study consisting of 23 healthy male and female subjects, mirabegron peak plasma concentration (Cmax) increased by 45% and systemic exposure (AUC) increased by 80% when a single 100 mg dose of mirabegron was administered following multiple dosing of ketoconazole 400 mg daily for 9 days.  No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.', 'Metabolism', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245394/', '', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Oxybutynin, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237617, 'Pimecrolimus (topical)', 'Pazopanib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme.', 'DDInter', 'No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245400/', '', 'Dabrafenib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237618, 'Ropivacaine', 'Pazopanib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine.  Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.', 'DDInter', 'CYP450 3A4 inhibitors have a significant effect on the pharmacokinetics of ropivacaine only in the presence of CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, or mexiletine. Therefore, the combination of ropivacaine and the above drugs is not recommended.', 'Metabolism', 'CYP450 3A4 inhibitors have a significant effect on the pharmacokinetics of ropivacaine only in the presence of CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, or mexiletine.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245415/', '', 'Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More', 'Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237619, 'Sibutramine', 'Pazopanib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.', 'DDInter', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.  Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.  The data suggest that although the potential for such interaction exists, the magnitude appears to be small.  No special precaution appears necessary; however, dosage adjustments as well as clinical and laboratory monitoring may be appropriate in some cases when a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245434/', '', 'Dacomitinib, Tepotinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, More', 'Dexfenfluramine, Ephedrine, Fenfluramine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237620, 'Tivozanib', 'Pazopanib', 'Moderate', 'Coadministration with tivozanib may increase the plasma concentrations and therapeutic effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tivozanib.', 'DDInter', 'Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.  If coadministration is necessary, the manufacturer suggests separating the administration times by 2 or more hours.', 'Absorption', 'Caution and clinical monitoring are advised if tivozanib is prescribed with orally administered drugs that are sensitive substrates for BCRP, such as rosuvastatin.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245445/', '', 'Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More', 'Regorafenib, Copanlisib, Abemaciclib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Afatinib, Dacomitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237621, 'Tolterodine', 'Pazopanib', 'Moderate', 'Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered.  Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.', 'DDInter', 'The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.  Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.', 'Metabolism', 'The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245446/', '', 'Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Oxybutynin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237622, 'Ulipristal', 'Pazopanib', 'Minor', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.', 'Metabolism', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245450/', '', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', 'Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237623, 'Yellow Fever Vaccine', 'Pazopanib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245454/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237624, 'Zonisamide', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme.', 'DDInter', 'Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.', 'Metabolism', 'Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245455/', '', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237625, 'Varicella Zoster Vaccine (Recombinant)', 'Pazopanib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245456/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237626, 'Drospirenone', 'Voxelotor', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245464/', '', 'Megestrol acetate, Etynodiol, Levonorgestrel, Estetrol, Norgestrel, Megestrol acetate, Etynodiol, Levonorgestrel, Progesterone, Norgestrel', 'Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237627, 'Voxelotor', 'Lefamulin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-gp may increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.  When oral lefamulin was administered with oral ketoconazole, a potent CYP450 3A4/P-gp inhibitor, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 58% and 165%, respectively.', 'DDInter', 'Caution is advised when lefamulin is used with CYP450 3A4 and/or P-gp inhibitors.  Patients should be monitored for increased adverse effects and seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Caution is advised when lefamulin is used with CYP450 3A4 and/or P-gp inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245470/', '', 'Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237628, 'Voxelotor', 'Propafenone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of propafenone, which may result in proarrhythmic events and exaggerated beta-adrenergic blocking activity.', 'DDInter', 'Caution is advised when propafenone is administered with CYP450 3A4 inhibitors.  Therapeutic response to propafenone as well as clinical and electrocardiographic evidence of toxicity should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the propafenone dosage adjusted as necessary.  Patients should be monitored for potential adverse effects such as new or worsening arrhythmias or heart failure, edema, bradycardia, and atrioventricular block.  Simultaneous use of propafenone with both a CYP450 3A4 inhibitor and a CYP450 2D6 inhibitor (or in patients with CYP450 2D6 deficiency) should be avoided.', 'Metabolism', 'Caution is advised when propafenone is administered with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245480/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237629, 'Voxelotor', 'Tramadol', 'Moderate', 'Coadministration with drugs that are inhibitors of the CYP450 3A4 isoenzymes may increase the plasma concentrations of tramadol and its active O-demethylated metabolite.', 'DDInter', 'Caution is advised if tramadol is used concomitantly with medications that inhibit CYP450 3A4 metabolism.  Dosage adjustments as well as clinical monitoring may be appropriate whenever there drugs are added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if tramadol is used concomitantly with medications that inhibit CYP450 3A4 metabolism.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245489/', '', 'Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237630, 'Voxelotor', 'Ulipristal', 'Minor', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.', 'Metabolism', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245490/', '', 'Megestrol acetate, Etynodiol, Levonorgestrel, Estetrol, Norgestrel, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237631, 'Voxelotor', 'Venetoclax', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.  If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%.  The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.', 'Metabolism', 'Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245491/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237632, 'Brexpiprazole', 'Pitolisant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of brexpiprazole.  In vitro and in vivo data indicate that brexpiprazole is metabolized primarily by CYP450 3A4 and 2D6.', 'DDInter', 'Pharmacologic response to brexpiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the brexpiprazole dosage adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245500/', '', 'Quetiapine, Thiothixene, Loxapine, Molindone, Lurasidone', 'Dalfampridine, Inotersen, Riluzole, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237633, 'Bromocriptine', 'Pitolisant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bromocriptine.', 'DDInter', 'The potential for diminished pharmacologic effects of bromocriptine should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bromocriptine should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245501/', '', 'Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Tolcapone, Rotigotine, Pergolide, Pramipexole, Safinamide, More', 'Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237634, 'Butorphanol', 'Pitolisant', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.', 'DDInter', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245502/', '', 'Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, Naloxone, Nalbuphine', 'Dalfampridine, Inotersen, Riluzole, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237635, 'Cariprazine', 'Pitolisant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites.', 'DDInter', 'Concomitant use of cariprazine with CYP450 3A4 inducers has not been evaluated and is not recommended.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245503/', '', 'Quetiapine, Thiothixene, Loxapine, Molindone, Lurasidone', 'Dalfampridine, Inotersen, Riluzole, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237636, 'Hydrocodone', 'Pitolisant', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.', 'DDInter', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245512/', '', 'Dextromethorphan, Clofedanol, Benzonatate, Pentoxyverine, Codeine', 'Dalfampridine, Inotersen, Riluzole, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237637, 'Pitolisant', 'Oxycodone', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.', 'DDInter', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245523/', '', 'Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, Naloxone, Nalbuphine', 'Dalfampridine, Inotersen, Riluzole, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237638, 'Pitolisant', 'Perampanel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.', 'DDInter', 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245524/', '', 'Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More', 'Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237639, 'Siponimod', 'Pitolisant', 'Major', 'Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.  Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.  Advice from a cardiologist should be sought if treatment with siponimod is considered in patients on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes or drugs that slow heart rate or AV conduction.', 'Synergism', 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245529/', '', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237640, 'Somapacitan', 'Pitolisant', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245532/', '', 'Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237641, 'Somatrem', 'Pitolisant', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245533/', '', 'Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237642, 'Ulipristal', 'Pitolisant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite.  Based on in vitro and pharmacokinetic data, ulipristal acetate is thought to be primarily metabolized by CYP450 3A4 to mono-demethylated and di-demethylated metabolites.', 'DDInter', 'When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.  For patients who have used enzyme-inducing drugs within the past 4 weeks and are seeking emergency contraception, ulipristal acetate is not recommended and a non-hormonal method (i.e.  a copper intrauterine device (Cu-IUD)) should be considered.', 'Metabolism', 'When used to prevent pregnancy, ulipristal acetate should not be coadministered with CYP450 3A4 inducers due to the potential for loss of therapeutic efficacy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245539/', '', 'Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', 'Megestrol acetate, Estetrol, Estradiol, Medroxyprogesterone acetate, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237643, 'Daclatasvir', 'Semaglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245544/', '', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237644, 'Fluocinolone acetonide', 'Semaglutide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.', 'DDInter', 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'Antagonism', 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245545/', '', 'Fluorometholone, Indomethacin, Diclofenac, Hydrocortisone butyrate, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinonide, Isosorbide dinitrate, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237645, 'Semaglutide', 'Simeprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245551/', '', 'Guar gum', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237646, 'Sofosbuvir', 'Semaglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245553/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237647, 'Acrivastine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245555/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237648, 'Amobarbital', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245556/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237649, 'Safinamide', 'Asenapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245558/', '', 'Amisulpride, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237650, 'Safinamide', 'Azatadine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245559/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Entacapone, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237651, 'Safinamide', 'Azelastine (nasal)', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245560/', '', 'Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237652, 'Baclofen', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245561/', '', 'Tizanidine', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237653, 'Benzatropine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245562/', '', 'Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237654, 'Brexpiprazole', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245564/', '', 'Amisulpride, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237655, 'Brivaracetam', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245565/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237656, 'Bromocriptine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245566/', '', 'Apomorphine, Cabergoline, Amantadine, Rasagiline, Selegiline, Safinamide, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Naproxen, Ibuprofen', 'Amantadine, Bromocriptine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237657, 'Brompheniramine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245567/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237658, 'Butabarbital', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245568/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237659, 'Butalbital', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245569/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237660, 'Butorphanol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245570/', '', 'Naltrexone, Naloxone, Oxycodone, Acetaminophen, Ibuprofen, Celecoxib, Codeine, Acetylsalicylic acid, Buprenorphine, Nalbuphine', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237661, 'Cannabidiol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245572/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237662, 'Carbamazepine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245574/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237663, 'Carbinoxamine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245575/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237664, 'Cariprazine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245576/', '', 'Amisulpride, Pimavanserin', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237665, 'Carisoprodol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245577/', '', 'Tizanidine', 'Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237666, 'Cenobamate', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245578/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237667, 'Clofedanol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245579/', '', 'Benzonatate, Codeine', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237668, 'Chloral hydrate', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245580/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237669, 'Chlorcyclizine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245581/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237670, 'Chlordiazepoxide', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245582/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237671, 'Chlormezanone', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245583/', '', 'Tizanidine', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237672, 'Chlorphenesin', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245584/', '', 'Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237673, 'Chlorzoxazone', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245585/', '', 'Tizanidine', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237674, 'Clemastine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245586/', '', 'Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Selegiline, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237675, 'Clobazam', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245587/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237676, 'Clorazepic acid', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245588/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237677, 'Clozapine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245589/', '', 'Amisulpride, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237678, 'Cyclizine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245590/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237679, 'Cyproheptadine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245591/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237680, 'Dantrolene', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245592/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237681, 'Dexmedetomidine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245595/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237682, 'Dezocine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245596/', '', 'Naltrexone, Naloxone, Oxycodone, Acetaminophen, Ibuprofen, Celecoxib, Codeine, Acetylsalicylic acid, Buprenorphine, Nalbuphine', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237683, 'Diazepam', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245597/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237684, 'Dimenhydrinate', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245599/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237685, 'Doxylamine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245600/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237686, 'Dronabinol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245601/', '', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237687, 'Droperidol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245602/', '', 'Amisulpride, Pimavanserin', 'Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237688, 'Entacapone', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245604/', '', 'Apomorphine, Cabergoline, Amantadine, Rasagiline, Selegiline, Safinamide', 'Entacapone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237689, 'Eslicarbazepine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245605/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237690, 'Estazolam', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245606/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237691, 'Eszopiclone', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245607/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237692, 'Ethchlorvynol', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245609/', '', 'Nitrazepam, Zopiclone', 'Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237693, 'Ethosuximide', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245610/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237694, 'Ethotoin', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245611/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237695, 'Ezogabine', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245612/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237696, 'Felbamate', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245613/', '', 'Lacosamide', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237697, 'Flavoxate', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245614/', '', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, More', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237698, 'Flurazepam', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245615/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237699, 'Fosphenytoin', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245616/', '', 'Lacosamide', 'Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (237700, 'Gabapentin', 'Safinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/245618/', '', 'Lacosamide', '', 1767369485);
